Lilly's triple agonist just became its most powerful obesity drug yet Positive results in metabolic disease, a possible vaccine to treat the current Ebola outbreak, new cancer drug targets, and more led the news this week. Written byDDN editorial team

https://www.drugdiscoverynews.com/lilly-s-triple-agonist-just-became-its-most-powerful-obesity-drug-yet-17377?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_8UNGs9XnQMeGP67zJ9wcnTEbfLetfH5DlguUl4JrT3b9BXyXaeMU9GKOZfJ6oJ6LF16FyVsWvVIyzr_8spCQgDS3UIg&_hsmi=429953149&utm_content=429953149&utm_source=hs_email Lilly's triple agonist retatrutide posts its strongest weight loss numbers yet, setting up a 2027 FDA filing Eli Lilly, this week, reported positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials of retatrutide, a once-weekly injectable that activates receptors for GIP, GLP-1, and glucagon simultaneously — a triple mechanism that no approved obesity therapy currently matches. In TRIUMPH-2, adults with obesity and type 2 diabetes lost up to an average of 49.6 pounds, or 20.8 percent of body weight, at 80 weeks on the highest 12mg dose, with A1C dropping by an average of 1.5 percent. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 55.8 pounds, or 22.6 percent. Cardiovascular event data from TRIUMPH-3 trended favorably but the trial was not powered to draw conclusions on that endpoint. The drug also produced notable reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, and the inflammatory marker hsCRP. Lilly plans to file a Biologics License Application with the FDA in Q1 2027, with the same data package supporting additional submissions for knee osteoarthritis pain and obstructive sleep apnea. Five consecutive positive Phase 3 readouts across the TRIUMPH program now give Lilly a credible path to fielding three distinct obesity medicines at once. – Andrea Corona